Another mpox vaccine, LC16, made by Japan's KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

WHO authorizes Bavarian Nordic vaccine for mpox, offering hope for countries battling the disease. Vaccine can be used off-label for children and immunocompromised individuals.

WHO approves second mpox vaccine The emergency use listing authorisation by WHO paves the way for countries worldwide to quickly approve and import the vaccine for distribution Published: Wed 20 ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

WHO approves second mpox vaccine. Sign up now: Get ST's newsletters delivered to your inbox. The WHO on Nov 19 approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use.

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...

WHO approves Bavarian Nordic's Jynneos vaccine for adolescents aged 12-17 to combat global mpox outbreak. Children, adolescents and those with weakened immune systems have been particularly ...

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8. The WHO declared mpox a global public health emergency for the second time in two years in ...

The World Health Organisation (WHO) said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks ...